Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design

Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.